Trial Profile
Lenalidomide Plus Melphalan as a Preparative Regimen for Autologous Stem Cell Transplantation in Relapsed Multiple Myeloma: A Phase 1 / 2 Study
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 06 Feb 2024
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary) ; Melphalan
- Indications Multiple myeloma
- Focus Adverse reactions
- 30 Jan 2024 Planned End Date changed from 1 Dec 2025 to 1 Dec 2024.
- 30 Jan 2024 Planned primary completion date changed from 1 Dec 2023 to 1 Dec 2024.
- 24 Jan 2023 Planned primary completion date changed from 1 Dec 2022 to 1 Dec 2023.